PureTech

We are incredibly proud to have won the 2026 #PrixGalien USA Award in the Incubators, Accelerators and Equity category!

This recognition is a testament to more than 2 decades of translating promising science into medicines that make a meaningful difference for patients, & it reflects the dedication of our employees and collaborators - past and present - who have helped make this achievement possible.

Thank you to @GalienFdn & its esteemed judges for this honor. bit.ly/3UWTI9R

Thank you to Guenther Koehne M.D., Ph.D. for detailing the Phase 1b results with LYT-200 in relapsed/refractory high-risk #MyelodysplasticSyndromes (HR-MDS) and #acutemyeloidleukemia at #ESMO26!

The presentation highlighted the favorable safety profile and encouraging clinical activity demonstrated in heavily pretreated patients, including 2 MRD-negative complete responses enabling stem cell transplantation in patients with R/R HR-MDS.

Learn more about the results and Gallop Oncology's plans to advance LYT-200 into Phase 2 development: bit.ly/4iGJsLW

Today, on #MDSWorldAwarenessDay, we join the global community in raising awareness of #myelodysplasticsyndromes (MDS) and supporting patients and families affected by these diseases. This year’s theme, “Understanding Your Treatment Options,” underscores the importance of education and continued progress in advancing new treatments for patients.

This year's observance comes on the heels of an important milestone for our Founded Entity, Gallop Oncology, as Guenther Koehne, MD, PhD, presented Phase 1b results for LYT-200 in relapsed/refractory high-risk MDS and #acutemyeloidleukemia during an oral presentation at #ESMO26 yesterday.

We are proud to be part of the broader research community dedicated to advancing new therapeutic approaches for patients with significant unmet medical needs.

Yesterday, members of the PureTech and Gallop Oncology teams participated in #MoveForMDS Boston in support of patients and families affected by #myelodysplasticsyndromes (MDS).

We are proud to join the @MDSFoundation and the local MDS community to raise awareness and support continued progress for those impacted by this disease.

Thank you to everyone who made it such a meaningful day!

The Gallop Oncology team will be onsite at #ESMO26, where Phase 1b results for LYT-200 will be presented in an oral proffered paper session.

Guenther Koehne, MD, PhD, will highlight encouraging clinical activity and favorable safety observed in heavily pretreated patients with relapsed/refractory high-risk #MyelodysplasticSyndromes and #AcuteMyeloidLeukemia. These findings reinforce the potential of LYT-200 as a first-in-class, mutation-agnostic treatment option.

Learn more about the upcoming presentation and Gallop’s plans to advance LYT-200 into Phase 2 development: bit.ly/4dKKqEd